undamentalytics Newsletter
Sign in

Goodrx Holdings, Inc. income statement

In fiscal 2025, Goodrx Holdings, Inc. reported revenue of $797m, up 0.6% on the year before, operating income of $87.5m (a 11.0% margin) and net income of $30.4m, or $0.09 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue250388551745767750792797785
Research and development442962126143136124121117
Selling and marketing104177255370358341367332325
General and administrative815461155145126118114108
Operating income77140−276132−27668775
Interest expense225028243457534341
Income before tax5283−303−10−23−56315741
Income tax917−101510−47152625
Net income4466−294−25−33−9163016
Diluted EPS$0.06$0.18−$1.07−$0.06−$0.08−$0.02$0.04$0.09$0.05
Diluted shares (average)237m231m275m410m413m410m392m357m345m
EBITDA87153−257485681135173164

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: DOCS vs GDRXGDRX vs PHRGDRX vs OMCLGDRX vs WAY

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Goodrx Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Goodrx Holdings, Inc.